0000000000367803

AUTHOR

Melanie Kaiser

showing 9 related works from this author

PanCareLIFE

2018

Aims: Survival after cancer diagnosed during childhood or adolescence continues to improve with new treatments and supportive therapies. Optimal long-term care requires that risks to vulnerable organs are clearly defined and translated into guidelines that are implemented into practice. PanCareLIFE is a pan-European consortium that addresses survivorship issues comprising fertility, hearing impairment and quality of life. This article describes the scientific basis of PanCareLIFE's studies.Methods: PanCareLIFE involves 17 partner institutions from eight European countries, with additional 11 data providers from five other countries. Study designs and methods include molecular genetic, cohor…

MaleGerontologyCancer ResearchLongitudinal studyMedizinPilot ProjectsChildhood cancer survivors0302 clinical medicineNeoplasmsLYMPHOMAMedicineFertility preservationChild610 Medicine & healthEARLY MENOPAUSEOVARIAN-FUNCTIONmedia_commonSURVIVORSOUTCOMES030219 obstetrics & reproductive medicineFertility PreservationGENETIC-VARIATIONCHEMOTHERAPYEuropeOncologyChild Preschool030220 oncology & carcinogenesisCohortFemalemedicine.symptom360 Social problems & social servicesAdultQuality of lifeAdolescentHearing lossmedia_common.quotation_subjectFertilityGuidelinesYoung Adult03 medical and health sciencesQuality of life (healthcare)SDG 3 - Good Health and Well-beingHumansCHILDHOOD-CANCERbusiness.industryClinical study designLate effectsHEARING-LOSSInfant NewbornInfantOtotoxicityLong-Term CareGonadal impairmentLong-term careFeasibility StudiesbusinessFOLLOW-UPEuropean Journal of Cancer
researchProduct

Effect of genetic variation in CYP450 on Gonadal impairment in a European cohort of female childhood cancer survivors, based on a candidate gene appr…

2021

Background: Female childhood cancer survivors (CCSs) carry a risk of therapy-related gonadal dysfunction. Alkylating agents (AA) are well-established risk factors, yet inter-individual variability in ovarian function is observed. Polymorphisms in CYP450 enzymes may explain this variability in AA-induced ovarian damage. We aimed to evaluate associations between previously identified genetic polymorphisms in CYP450 enzymes and AA-related ovarian function among adult CCSs. Methods: Anti-Müllerian hormone (AMH) levels served as a proxy for ovarian function in a discovery cohort of adult female CCSs, from the pan-European PanCareLIFE cohort (n = 743

OncologyInfertilityCancer ResearchCandidate genemedicine.medical_specialtyendocrine systemendocrine system diseasesMedizinAnti-Müllerian hormoneArticleHealthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18]Childhood cancer survivors03 medical and health sciences0302 clinical medicineSDG 3 - Good Health and Well-beingInterquartile rangeInternal medicineGenetic variationGenetic modelmedicineChemotherapyFertility preservationRC254-282030304 developmental biology0303 health sciencesbiologybusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensAnti-Müllerian hormonemedicine.diseaseOvarian functionCytochrome P450 genesWomen's cancers Radboud Institute for Health Sciences [Radboudumc 17]3. Good healthOncology030220 oncology & carcinogenesisCohortbiology.proteinCandidate gene approachbusinessGeneral Economics Econometrics and FinanceCancers
researchProduct

Invitation to cervical cancer screening does increase participation in Germany: Results from the MARZY study

2016

The effect of different invitation models on participation in cervical cancer screening (CCS) was investigated in a randomized population-based cohort study in Germany. Participants were randomly selected via population registries and randomized into intervention Arm A (invitation letter) and Arm B (invitation letter and information brochure) or control Arm C (no invitation). The intervention and control arms were compared with regard to 3-year participation and the two invitation models were compared between intervention arms. Of the 7,758 eligible women aged 30-65 years, living in the city of Mainz and in the rural region of Mainz-Bingen, 5,265 were included in the analysis. Differences i…

Cancer Researchmedicine.medical_specialtyeducation.field_of_studybusiness.industryPopulationIntervention groupOdds ratioCervical cancer screeningLogistic regressionConfidence interval03 medical and health sciences0302 clinical medicineOncology030220 oncology & carcinogenesisPhysical therapymedicine030212 general & internal medicineeducationbusinessDemographyCohort studySchool educationInternational Journal of Cancer
researchProduct

Cancer in Children With Fanconi Anemia and Ataxia-Telangiectasia—A Nationwide Register-Based Cohort Study in Germany

2021

PURPOSE Fanconi anemia (FA) and ataxia-telangiectasia (AT) are rare inherited syndromes characterized by abnormal DNA damage response and caused by pathogenic variants in key DNA repair proteins that are also relevant in the pathogenesis of breast cancer and other cancer types. The risk of cancer in children with these diseases is poorly understood and has never been assessed in a population-based cohort before. METHODS We identified 421 patients with FA and 160 patients with AT diagnosed between 1973 and 2020 through German DNA repair disorder reference laboratories. We linked patients' laboratory data with childhood cancer data from the German Childhood Cancer Registry. RESULTS Among 421 …

MaleOncologyRegister basedCancer Researchmedicine.medical_specialtyTime FactorsAdolescentDNA damageAnemiaDNA repairRisk AssessmentAtaxia TelangiectasiaRisk FactorsFanconi anemiaGermanyNeoplasmsInternal medicinemedicineHumansRegistriesChildbusiness.industryIncidenceAge FactorsInfantCancerPrognosismedicine.diseaseFanconi AnemiaOncologyChild PreschoolAtaxia-telangiectasiaFemalebusinessCohort studyJournal of Clinical Oncology
researchProduct

Health-related quality of life in European childhood cancer survivors: Protocol for a study within PanCareLIFE

2021

Background Survival after childhood cancer has improved to more than 80% during the last few years, leading to an increased number of childhood cancer survivors. Cancer itself, or its treatment, may cause chronic health conditions, including somatic and mental sequelae, which may affect survivors’ health-related quality of life (HRQoL). Objective The project PanCareLIFE aims to establish a large database with comprehensive data on childhood cancer survivors from different European countries, including data on HRQoL. Within PanCareLIFE, this study aims to describe HRQoL in survivors, investigate predictors of HRQoL, and describe the association of HRQoL with hearing and female fertility imp…

Pediatricsmedicine.medical_specialtymedia_common.quotation_subjectComputer applications to medicine. Medical informaticsChildhood cancerR858-859.7Medizinneoplasms610 Medicine & healthhealth statusFertility03 medical and health sciences0302 clinical medicinechildrenQuality of lifeSDG 3 - Good Health and Well-being360 Social problems & social servicesEpidemiologyProtocolMedicineadolescents030212 general & internal medicinemedia_commonHealth related quality of lifebusiness.industryRQuestionnaireCancersurvivors of childhood cancerGeneral Medicinemedicine.diseasehumanities3. Good healthEuropequality of life030220 oncology & carcinogenesisCohortMedicineepidemiologybusinessJMIR Research Protocols
researchProduct

Association of candidate pharmacogenetic markers with platinum-induced ototoxicity

2020

Genetic association studies suggest a genetic predisposition for cisplatin-induced ototoxicity. Among other candidate genes, thiopurine methyltransferase (TPMT) is considered a critical gene for susceptibility to cisplatin-induced hearing loss in a pharmacogenetic guideline. The PanCareLIFE cross-sectional cohort study evaluated the genetic associations in a large pan-European population and assessed the diagnostic accuracy of the genetic markers. 1,112 pediatric cancer survivors who had provided biomaterial for genotyping were screened for participation in the pharmacogenetic association study. 900 participants qualified for inclusion. Based on the assessment of original audiograms, patien…

OncologyDrug-induced ototoxicitymedicine.medical_specialtyCandidate geneHearing lossMulticenter cohort studyCancer survivorsPopulationAdverse drug reaction610 Medicine & healthlcsh:Computer applications to medicine. Medical informatics03 medical and health sciences0302 clinical medicine360 Social problems & social servicesInternal medicinemedicineGenetic predisposition610 Medicine & healtheducationlcsh:Science (General)030304 developmental biologyGenetic association0303 health scienceseducation.field_of_studyMultidisciplinaryThiopurine methyltransferasebiologycarboplatin [Cisplatin]business.industryMedicine and DentistryPediatric cancerCisplatin: carboplatinPharmacogeneticsbiology.proteinlcsh:R858-859.7Genetic markersmedicine.symptombusinessChildhood cancer360 Social problems & social services030217 neurology & neurosurgeryPharmacogeneticslcsh:Q1-390Data in brief
researchProduct

Risk of digestive cancers in a cohort of 69 460 five-year survivors of childhood cancer in Europe: the PanCareSurFup study.

2021

BackgroundSurvivors of childhood cancer are at risk of subsequent primary neoplasms (SPNs), but the risk of developing specific digestive SPNs beyond age 40 years remains uncertain. We investigated risks of specific digestive SPNs within the largest available cohort worldwide.MethodsThe PanCareSurFup cohort includes 69 460 five-year survivors of childhood cancer from 12 countries in Europe. Risks of digestive SPNs were quantified using standardised incidence ratios (SIRs), absolute excess risks and cumulative incidence.Results427 digestive SPNs (214 colorectal, 62 liver, 48 stomach, 44 pancreas, 59 other) were diagnosed in 413 survivors. Wilms tumour (WT) and Hodgkin lymphoma (HL) survivors…

medicine.medical_specialtyColorectal cancerPopulation03 medical and health sciences0302 clinical medicineInternal medicineEpidemiology of cancerCOLORECTAL CANCER SCREENINGmedicineCumulative incidence030212 general & internal medicineGastrointestinal cancerFamily historyeducation610 Medicine & healthGASTROINTESTINAL CANCERCOLORECTAL CANCEReducation.field_of_studybusiness.industryIncidence (epidemiology)Gastroenterologymedicine.disease030220 oncology & carcinogenesisCohortCANCER EPIDEMIOLOGYbusiness360 Social problems & social servicesGut
researchProduct

Qualitätssicherung in einer epidemiologischen Kohortenstudie: Durchführung von on-site Monitoring in gynäkologischen Arztpraxen

2014

Quality assurance is required for all relevant instruments and procedures in epidemiological studies just like for clinical trials. The structure and complexity of the monitoring was developed based on the monitoring in clinical trials and applied to an epidemiological cohort study on early detection of cervical cancer (MARZY Study). Analyses of the on-site monitoring in participating gynaecological practices during the baseline investigation of the MARZY cohort were presented. The baseline investigation of the MARZY study was conducted between 2005 and 2007 in the city of Mainz, the rural district of Mainz-Bingen and surrounding areas. Women, who were randomly selected via population regis…

Cervical cancermedicine.medical_specialtyeducation.field_of_studybusiness.industryHealth PolicyPopulationMedicine (miscellaneous)medicine.diseaseEducationClinical trialMonitoring in clinical trialsInformed consentFamily medicineEpidemiologyCohortmedicineeducationbusinessCohort studyZeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen
researchProduct

Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the Europe…

2020

Background Irreversible sensorineural hearing loss is a common side effect of platinum treatment with the potential to significantly impair the neurocognitive, social and educational development of childhood cancer survivors. Genetic association studies suggest a genetic predisposition for cisplatin-induced ototoxicity. Among other candidate genes, thiopurine methyltransferase (TPMT) is considered a critical gene for susceptibility to cisplatin-induced hearing loss in the FDA drug label and a pharmacogenetic guideline. The aim of this cross-sectional cohort study was to confirm the genetic associations in a large pan-European population and to evaluate the diagnostic accuracy of the genetic…

0301 basic medicineOncologyMaleCancer ResearchCandidate genePharmacogenomic VariantsCancer survivorsCHILDRENAnti-neoplastic drugsVARIANTSOCT2Carboplatin0302 clinical medicineHearingRisk FactorsNeoplasmsTPMTHearing / drug effectsProspective StudiesAge of OnsetChild610 Medicine & healthPREDICTORSmedia_commonHearing Loss Sensorineural / physiopathologyeducation.field_of_studyddc:618Thiopurine methyltransferasebiologycarboplatin [Cisplatin]Neoplasms / drug therapyOrganic Cation Transporter 2EuropeOncologyCisplatin: carboplatinCisplatin / adverse effects030220 oncology & carcinogenesisChild PreschoolOrganic Cation Transporter 2 / geneticsFemaleSENSITIVITYChildhood cancer360 Social problems & social servicesCohort studyDrug-induced ototoxicitymedicine.medical_specialtyINDUCED HEARING-LOSSAdolescentMulticenter cohort studyHearing Loss SensorineuralPopulationAdverse drug reactionAntineoplastic AgentsPolymorphism Single NucleotideRisk AssessmentHearing Loss Sensorineural / chemically inducedCarboplatin / adverse effects03 medical and health sciencesACYP2OtotoxicitySDG 3 - Good Health and Well-beingInternal medicinemedicineGenetic predispositionmedia_common.cataloged_instanceHumansGenetic Predisposition to DiseaseCISPLATIN-INDUCED OTOTOXICITYEuropean unioneducationGenetic Association StudiesGenetic associationRetrospective Studiesbusiness.industryAntineoplastic Agents / adverse effectsInfant NewbornInfantOdds ratioGuidelinemedicine.diseaseOtotoxicityCOMTPharmacogenomic Testing030104 developmental biologyCross-Sectional StudiesPharmacogeneticsbiology.proteinGenetic markersHearing Loss Sensorineural / geneticsCisplatinbusinessPharmacogenetics
researchProduct